Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 30.20
-0.32 (-1.05%)
At close: Feb 13, 2026
Kexing Biopharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,513 | 1,403 | 1,256 | 1,300 | 1,285 | 1,220 |
Other Revenue | 3.52 | 3.52 | 3.19 | 15.84 | 0.45 | 0.43 |
| 1,516 | 1,407 | 1,259 | 1,316 | 1,285 | 1,220 | |
Revenue Growth (YoY) | 14.16% | 11.75% | -4.32% | 2.39% | 5.32% | 2.48% |
Cost of Revenue | 549.65 | 444.2 | 370.31 | 324.66 | 265.3 | 245.24 |
Gross Profit | 966.66 | 962.73 | 888.72 | 991.21 | 1,020 | 975.05 |
Selling, General & Admin | 659.87 | 682.73 | 776.11 | 913.6 | 846.08 | 726.77 |
Research & Development | 187.22 | 168.05 | 344.8 | 193.3 | 122.95 | 58.07 |
Other Operating Expenses | 20.79 | 12.03 | 11.46 | 9.69 | 9.78 | 9.42 |
Operating Expenses | 870.79 | 864.21 | 1,129 | 1,117 | 977.66 | 796.49 |
Operating Income | 95.86 | 98.52 | -240.71 | -125.34 | 42.21 | 178.56 |
Interest Expense | -43.32 | -44.85 | -40.72 | -28.7 | -8.03 | -10.33 |
Interest & Investment Income | 33.48 | 12.95 | 13.17 | 9.49 | 18.25 | 0.94 |
Currency Exchange Gain (Loss) | 0.74 | 0.74 | 3.29 | 6.95 | -1.53 | -5.03 |
Other Non Operating Income (Expenses) | 10.21 | -0.58 | -0.76 | -1.78 | -3.88 | -6.58 |
EBT Excluding Unusual Items | 96.98 | 66.78 | -265.72 | -139.39 | 47.03 | 157.56 |
Gain (Loss) on Sale of Investments | 0.19 | -29.19 | 0.24 | -5.35 | 47.46 | - |
Gain (Loss) on Sale of Assets | 0.95 | 0.08 | 0.28 | 1.05 | -2.74 | -0.49 |
Asset Writedown | 0.82 | -0.17 | -1.6 | - | - | - |
Other Unusual Items | 23.41 | 19.41 | 6.73 | 4.63 | 3.88 | 2.08 |
Pretax Income | 122.35 | 56.9 | -260.07 | -139.06 | 95.63 | 159.16 |
Income Tax Expense | -0.05 | 29.85 | -64.58 | -46.24 | -0.84 | 20.02 |
Earnings From Continuing Operations | 122.4 | 27.05 | -195.49 | -92.82 | 96.46 | 139.14 |
Minority Interest in Earnings | 3.16 | 4.43 | 5.2 | 2.53 | - | - |
Net Income | 125.57 | 31.48 | -190.29 | -90.3 | 96.46 | 139.14 |
Net Income to Common | 125.57 | 31.48 | -190.29 | -90.3 | 96.46 | 139.14 |
Net Income Growth | - | - | - | - | -30.67% | -12.94% |
Shares Outstanding (Basic) | 203 | 197 | 198 | 201 | 197 | 150 |
Shares Outstanding (Diluted) | 203 | 197 | 198 | 201 | 197 | 150 |
Shares Change (YoY) | 6.36% | -0.74% | -1.21% | 1.93% | 31.59% | 0.17% |
EPS (Basic) | 0.62 | 0.16 | -0.96 | -0.45 | 0.49 | 0.93 |
EPS (Diluted) | 0.62 | 0.16 | -0.96 | -0.45 | 0.49 | 0.93 |
EPS Growth | - | - | - | - | -47.31% | -13.08% |
Free Cash Flow | -31.24 | 12.68 | -278.34 | -485.06 | -277.97 | -83.04 |
Free Cash Flow Per Share | -0.15 | 0.06 | -1.40 | -2.42 | -1.41 | -0.56 |
Dividend Per Share | 0.080 | 0.080 | - | - | 0.100 | 0.080 |
Dividend Growth | - | - | - | - | 25.00% | - |
Gross Margin | 63.75% | 68.43% | 70.59% | 75.33% | 79.36% | 79.90% |
Operating Margin | 6.32% | 7.00% | -19.12% | -9.53% | 3.28% | 14.63% |
Profit Margin | 8.28% | 2.24% | -15.11% | -6.86% | 7.51% | 11.40% |
Free Cash Flow Margin | -2.06% | 0.90% | -22.11% | -36.86% | -21.63% | -6.80% |
EBITDA | 191.7 | 184.6 | -167.64 | -70.32 | 77.41 | 207.7 |
EBITDA Margin | 12.64% | 13.12% | -13.31% | -5.34% | 6.02% | 17.02% |
D&A For EBITDA | 95.84 | 86.08 | 73.07 | 55.03 | 35.2 | 29.14 |
EBIT | 95.86 | 98.52 | -240.71 | -125.34 | 42.21 | 178.56 |
EBIT Margin | 6.32% | 7.00% | -19.12% | -9.53% | 3.28% | 14.63% |
Effective Tax Rate | - | 52.46% | - | - | - | 12.58% |
Revenue as Reported | 1,516 | 1,407 | 1,259 | 1,316 | 1,285 | 1,220 |
Advertising Expenses | - | - | - | - | 5.68 | 2.58 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.